Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q5T2R2

UPID:
DPS1_HUMAN

ALTERNATIVE NAMES:
All-trans-decaprenyl-diphosphate synthase subunit 1; Decaprenyl pyrophosphate synthase subunit 1; Decaprenyl-diphosphate synthase subunit 1; Solanesyl-diphosphate synthase subunit 1; Trans-prenyltransferase 1

ALTERNATIVE UPACC:
Q5T2R2; Q53F75; Q6P473; Q86WQ8; Q9Y2W5

BACKGROUND:
The enzyme All trans-polyprenyl-diphosphate synthase PDSS1, known for its role in the synthesis of ubiquinone side chains, is essential for cellular energy production. It functions by adding isopentenyl diphosphate molecules to farnesyl diphosphate, facilitating the production of ubiquinone-9 and ubiquinone-10.

THERAPEUTIC SIGNIFICANCE:
Given PDSS1's critical function in Coenzyme Q10 synthesis, its association with primary Coenzyme Q10 deficiency underscores the enzyme's therapeutic relevance. Targeting PDSS1 could offer a promising approach to treating related multisystem disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.